Treatment Algorithm for Stage IIB and Beyond Melanoma

Opinion
Video

Allison Betof Warner, MD, PhD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss treatment practices for patients with stage IIB and beyond melanoma.

Recent Videos
Related Content
Support for the planned biologics license application comes from data showing a 32.9% response rate with RP1 plus nivolumab for melanoma.

Pre-BLA Meeting Successful for RP1 Combo in Anti–PD-1–Failed Melanoma

Roman Fabbricatore
September 11th 2024
Article

Support for the planned biologics license application comes from data showing a 32.9% response rate with RP1 plus nivolumab for melanoma.

The safety profile of BNT111 plus cemiplimab was consistent with previous trials assessing BNT111 with anti–PD-L1 treatments.

BNT111/Cemiplimab Combo Significantly Improves ORR in Unresectable Melanoma

Roman Fabbricatore
July 30th 2024
Article

The safety profile of BNT111 plus cemiplimab was consistent with previous trials assessing BNT111 with anti–PD-L1 treatments.

Dabrafenib/Trametinib Yields Sustained Survival During Long-Term Follow-up in Advanced Melanoma

Dabrafenib/Trametinib Yields Sustained Survival During Long-Term Follow-up in Advanced Melanoma

Gina Mauro
June 1st 2024
Article

Continued survival was observed in dabrafenib/trametinib combination after 8 years follow-up in patients with advanced melanoma.

Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma

Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma

Omid Hamid, MD
April 19th 2024
Article

Omid Hamid, MD, gives his perspective on the use of tumor-infiltrating lymphocyte therapy for patients with melanoma.

Early FDG PET/CT Scanning May Predict Treatment Response in Melanoma

Early FDG PET/CT Scanning May Predict Treatment Response in Melanoma

Rina Lokaj
February 19th 2024
Article

Imaging after 1 week of treatment with pembrolizumab may help identify treatment responses in patients with metastatic melanoma.